Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 180 resultados
LastUpdate Última actualización 01/03/2026 [07:21:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
previousPage Resultados 175 a 180 de 180  

REGULATION OF GENES IN ULCERATIVE COLITIS AND THE USES THEREOF

NºPublicación:  AU2024224464A1 14/08/2025
Solicitante: 
ELI LILLY AND COMPANY
ELI LILLY AND COMPANY
AU_2024224464_A1

Resumen de: AU2024224464A1

The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.

Proteins and T-Cells Involved in Chronic Inflammatory Diseases

NºPublicación:  US2025258170A1 14/08/2025
Solicitante: 
CHRISTIAN ALBRECHTS UNIV ZU KIEL [DE]
Christian-Albrechts-Universit\u00E4t zu Kiel
US_2025258170_A1

Resumen de: US2025258170A1

A protein comprising an amino acid sequence according to SEQ ID NO: 1, wherein the amino acid in position 4 of SEQ ID NO: 1 is selected from the group consisting of N, S, R, T and I, preferably consisting of N, S and R and wherein the amino acid in position 5 of SEQ ID NO: 1 is selected from the group consisting of R, V, L, F, M, I, H, S, T, A, P and G, with the proviso that the amino acid sequence is not SEQ ID NO: 24.

SYSTEMS AND METHODS FOR DIAGNOSIS, RISK ASSESSMENT, AND/OR VIRTUAL TREATMENT ASSESSMENT OF VISCERAL ISCHEMIA

NºPublicación:  US2025255558A1 14/08/2025
Solicitante: 
HEARTFLOW INC [US]
Heartflow, Inc
US_2025255558_PA

Resumen de: US2025255558A1

Systems and methods are disclosed for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.

COMPOSITIONS AND METHODS FOR SENSING ENZYMATIC ACTIVITY

NºPublicación:  WO2025171261A1 14/08/2025
Solicitante: 
GEORGIA TECH RES INST [US]
GEORGIA TECH RESEARCH CORPORATION
WO_2025171261_PA

Resumen de: WO2025171261A1

Compounds are described herein for the detection of the activity of an enzyme. The compounds include a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule. Upon interaction of the recognition domain with the enzyme, the covalent bond is destroyed, rendering reporter molecule detectable by a chemical detection device. Methods of detecting enzymatic activity of a plurality of enzymes are also described herein. Such methods include reacting a compound (having a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule) with an enzyme, and identifying detectable reporter molecules with a chemical detection device.

SINGLE IMMUNOGLOBULIN INTERLEUKIN-1 RECEPTOR RELATED (SIGIRR) VARIANTS AND USES THEREOF

Nº publicación: ES3034207T3 13/08/2025

Solicitante:

REGENERON PHARMACEUTICALS INC
Regeneron Pharmaceuticals, Inc

MX_2020002643_A

Resumen de: MX2020002643A

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.

traducir